New York, NY -- (SBWIRE) -- 12/13/2013 -- StockMarketIntel.com issues a special report on the following stocks: Novacopper Inc (NYSEMKT:NCQ), Provectus Pharmaceuticals, Inc. (OTCMKTS:PVCT), Synta Pharmaceuticals Corp. (NASDAQ:SNTA), Sequenom, Inc. (NASDAQ:SQNM)
Novacopper Inc (NYSEMKT:NCQ) declined -3.50%, trading on 3.69 million shares, to end the trade at $1.38. The stock changed hands in a range of $1.35 to $1.57, bringing its market capitalization to about $75.89 million. If we look at its trading history of the past 52 weeks, the share price suffered a low of $1.35 and was moved to the maximum level of $2.28. NovaCopper Inc., an exploration-stage company, engages in the exploration and development of mineral properties in the United States. It holds interests in the Upper Kobuk Mineral projects that include Arctic project, a copper-zinc-lead-gold-silver project located in the Southern Brooks Range of northwest Alaska; and Bornite project, which contains a carbonate-hosted copper deposit located in northwest Alaska.
Is it the Right to Grab NCQ after the Recent Slump? Get Free Trend Analysis Here
Provectus Pharmaceuticals, Inc. (OTCMKTS:PVCT) added 16.22%, to complete the trading session at $1.29, with a total volume of 2.10 million shares. The stock, on average, trades on a volume of 564,332 shares. It floated in a range of $1.13 to $1.30 during the last trading session, with a beta value of 0.51. Its market capitalization now moved to about $180.57 million. In the past 52 weeks, the share price has not declined below $0.53 and above $1.30. Provectus Pharmaceuticals, Inc., a development-stage pharmaceutical company, engages in developing pharmaceuticals for oncology and dermatology indications. The company?s product line includes PV-10, a Phase II study completed drug candidate for metastatic melanoma, a Phase I study completed candidate for breast cancer, and a Phase I protocol expansion candidate for liver metastasis; and PH-10, a Phase IIc randomized study initiated drug candidate for the treatment of psoriasis, and Phase II study completed candidate for atopic dermatitis.
Why Should Investors Buy PVCT After The Recent Gain? Just Go Here and Find Out
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) recorded a gain of 3.01% and was in a range of $4.74-$5.31 before closing at $4.79. The stock completed the day with a total volume of 5.97 million shares, versus an average volume of 2.09 million shares. The share price hit its 52-week low of $3.70 and $11.88 was the best price. Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs for treating severe medical conditions, including cancer and chronic inflammatory diseases. The company has two drug candidates in clinical trials for treating multiple types of cancer and various drug candidates in the preclinical stage of development.
What was the Moving Force behind SNTA on Bullish Run? Read This Research Report
Sequenom, Inc. (NASDAQ:SQNM) declined -4.49% yesterday, bringing its market capitalization around $233.75 million. The share price, after opening at $2.06, made a high of $2.17 and hovered above $1.95 to end the day at $2.02. The total number of shares that changed hands during the session was 3.27 million shares, as compared to average trading volume of 3.03 million shares. Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs for treating severe medical conditions, including cancer and chronic inflammatory diseases.
Will SQNM Reach the Bottom after Yesterday’s Correction? Find Out Here
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)